Mirae Asset Global Investments Co. Ltd. Boosts Holdings in Kenvue Inc. (NYSE:KVUE)

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 38.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 406,467 shares of the company’s stock after buying an additional 113,157 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Kenvue were worth $8,677,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Y.D. More Investments Ltd boosted its stake in Kenvue by 15.7% during the fourth quarter. Y.D. More Investments Ltd now owns 6,513 shares of the company’s stock worth $139,000 after buying an additional 882 shares during the period. Stratos Wealth Partners LTD. boosted its position in shares of Kenvue by 4.7% during the 4th quarter. Stratos Wealth Partners LTD. now owns 13,461 shares of the company’s stock worth $287,000 after purchasing an additional 601 shares during the period. E. Ohman J or Asset Management AB acquired a new stake in Kenvue in the 4th quarter valued at approximately $1,793,000. Mather Group LLC. raised its position in Kenvue by 55.0% in the fourth quarter. Mather Group LLC. now owns 10,627 shares of the company’s stock valued at $227,000 after purchasing an additional 3,770 shares during the period. Finally, Flavin Financial Services Inc. purchased a new position in shares of Kenvue during the fourth quarter worth $964,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 2.2 %

Shares of KVUE stock opened at $20.23 on Friday. The firm has a 50-day moving average price of $21.61 and a 200 day moving average price of $21.93. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $38.79 billion, a price-to-earnings ratio of 36.78, a PEG ratio of 2.05 and a beta of 1.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 4.05%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research reports. Bank of America increased their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Canaccord Genuity Group reduced their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, JPMorgan Chase & Co. increased their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.